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ABSTRACT 
Background Substantial evidence links exposure to moderate or high doses of ionising radiation, 
particularly in childhood, with increased risk of leukaemia. The association of leukaemia with 
exposure to low-dose (<100 mSv) radiation is less certain, although this is the dose range most 
relevant to the general population. We aimed to estimate the risk of leukaemia associated with 
low-dose radiation exposure in childhood (age <21 years). 
Methods In this analysis of historical cohort studies, we pooled eligible cohorts reported up to 
June 30, 2014. We evaluated leukaemia and myeloid malignancy outcomes with the relevant 
International Classification of Diseases and International Classification of Diseases for Oncology 
definitions. Cohorts included had not been treated for malignant disease, had ≥5 cases of the 
pertinent diseases, and individual active bone marrow (ABM) dose estimates. We restricted 
analysis to individuals who were younger than 21 years at first irradiation with mean cumulative 
ABM doses of less than 100 mSv. Dose-response models were fitted by use of Poisson regression. 
The data were received in fully anonymised form by the statistical analyst. 
Findings We identified nine eligible cohorts from Canada, France, Japan, Sweden, the UK, and 
the USA, including 262 573 people who had been exposed to less than 100 mSv enrolled between 
June 4, 1915, and Dec 31, 2004. Mean follow-up was 19·63 years (SD 17.75) and mean cumulative 
ABM dose was 19·6 mSv (SD 22.7). 154 myeloid malignancies were identified (including 79 acute 
myeloid leukaemias, eight with myelodysplastic syndromes and 36 chronic myeloid leukaemias), 
and 40 acute lymphoblastic leukaemias, with 221 leukaemias (including otherwise unclassified 
leukaemias but  excluding chronic lymphocytic leukaemia) identified overall. The fitted relative 
risks at 100 mSv were 3·09 (95% CI 1·41–5·92; ptrend=0·008)  for acute myeloid leukaemia and 
myelodysplastic syndromes, 2·56 (1·09–5·06; ptrend=0·033) for acute myeloid leukaemia, and 5·66 
(1·35–19·71; ptrend=0·023) for acute lymphoblastic leukaemia. There was no clear dose-response 
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for chronic myeloid leukaemia (p=0·394). There were few indications of between-cohort 
heterogeneity or departure from linearity. For acute myeloid leukaemia and myelodysplastic 
syndromes and for acute lymphoblastic leukaemia, the dose-responses remained significant for 
doses of less than 50 mSv. Excess absolute risks at 100 mSv were in the range of 0·1–0·4 cases or 
deaths per 10 000 person-years. 
Interpretation The risks of acute myeloid leukaemia and acute lymphoblastic leukaemia were 
significantly increased after cumulative doses of ionising radiation of less than 100 mSv in 
childhood or adolescence, with an excess risk also apparent for radiation doses of less than 50 mSv 
for some endpoints. These findings support an increased risk of leukaemia associated with low-
dose exposure to radiation and imply that the current system of radiological protection is prudent 
and not overly protective. 
Funding National Cancer Institute Intramural Research Program and National Cancer 
Institute/NIH awards R03CA188614+R01CA197422. 
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INTRODUCTION 
Leukaemia is the main sentinel radiogenic malignancy; the red (active) bone marrow is among the 
most radiosensitive of any organ or tissue, and leukaemia generally appears sooner than any other 
cancer after exposure to ionising radiation 1. At moderate-to-high doses (>0.5 Sv) there is abundant 
evidence of radiation-related excess risk for most major leukaemia subtypes, in particular acute 
myeloid leukaemia, and chronic myeloid leukaemia, and to a lesser extent acute lymphoblastic 
leukaemia 1. There is little evidence of an association with chronic lymphocytic leukaemia 1, now 
classified as a non-Hodgkin lymphoma2. There is emerging evidence of radiogenic risk associated 
with myelodysplastic syndromes, a myeloid-lineage precursor to acute myeloid leukaemia 3. 
Particularly high excess relative risks of subsequent leukaemia have been reported following 
radiation exposure in childhood 1. Evidence of risk at lower doses is less well established, in 
particular at radiation doses to the active bone marrow (ABM) of 100 mSv or less (the level of 
dose often used to demarcate low dose1,4), with some claiming a threshold for leukaemia and other 
cancers, below which there is no excess cancer risk 5. Most population exposures are from natural 
background radiation, diagnostic medical tests, or occupational, and are typically low doses6, so 
evaluating risks in this dose range is critical for radiation-protection purposes.  
Because radiation exposure in childhood has been shown to confer the highest proportionally 
increased risks for subsequent leukaemia1, which are also higher than for any other malignancy, 
individuals with childhood exposures afford the best opportunity for studying low-dose cancer 
risks. Leukaemias are a rare cancer type and most individual studies do not have sufficient numbers 
of cases that have received low-dose ionising radiation exposure to provide adequate statistical 
power to estimate risk accurately.  To directly evaluate low dose leukaemia risk, we have therefore 
conducted a pooled analysis of eligible cohorts that have received radiation exposure at a young 
age to assess risks of leukaemia following low-dose (<100 mSv) exposure to external sources of 
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(predominantly photon) radiation, generally for medical diagnosis or treatment of benign 
conditions; lymphomas and multiple myeloma were not included because of evidence that these 
diseases have limited sensitivity to induction by radiation 1. We excluded any groups treated for 
malignant conditions, in which chemotherapy would potentially be a strong confounder. Particular 
emphasis was placed on known radiogenic leukaemia subtypes, specifically (a) acute myeloid 
leukaemia with/without myelodysplastic syndromes, (b) chronic myeloid leukaemia, (c) acute 
lymphoblastic leukaemia.  We also evaluated acute leukaemia and all leukaemia excluding chronic 
lymphocytic leukaemia for comparison with groupings used in earlier studies, and to include 
leukaemias (excluding chronic lymphocytic leukaemia) that are otherwise unspecified.  The 
primary hypothesis was that radiation would increase risk of all radiogenic leukaemia even at low 
doses. 
METHODS 
Study design and participants 
Overall study design 
We examined all available cohort studies reporting on or before 30th June 2014, with ≥5 
leukaemias or other myeloid malignancies receiving mean cumulative radiation doses to the ABM 
>0.005 Sv among people first exposed while aged <21 years. Particularly when subtype-specific 
analyses are performed, cohorts that include <5 malignancies would almost certainly be 
uninformative in cohort-stratified analyses. We excluded any studies of patients being treated for 
malignant disease, in which chemotherapy would potentially be a strong confounder. We required 
that the cohorts include cumulative ABM dose estimates for each individual, and we reviewed the 
quality and completeness of the dosimetry, as outlined in Web-appendix pp. 5-7. We identified 
eligible cohorts from the most recent comprehensive summaries by international committees1 
combined with recent literature reviews7 and PubMed literature searches (using the terms 
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“leukaemia” + “radiation” + “medical” + “diagnosis”, “leukaemia” + “radiation” + “medical” + 
“therapy”). The searches were conducted on a number of dates, and in final form on 29th May 
2018. The following ten cohorts met the eligibility criteria: the paediatrically-exposed (age at 
treatment <21 years) patients of the Massachusetts tuberculosis (TB) fluoroscopy cohort 8; the 
paediatrically-exposed (age at treatment <21 years) patients of the Canadian TB fluoroscopy 
cohort 9; the French haemangioma cohort 10; the Göteborg haemangioma cohort 11; the Stockholm 
haemangioma cohort12; the Israeli tinea capitis cohort13; the paediatrically-exposed (age at 
exposure <20 years) subjects of the Japanese atomic bomb survivor Life Span Study (LSS) cohort 
14; the Rochester thymus enlargement cohort 15; the US scoliosis cohort 16; and the UK-National 
Cancer Institute (NCI) computerised tomography (CT) cohort 3. Cohorts excluded were those in 
which subjects mostly received radiation exposures from internally deposited radionuclides, 
dosimetry was inadequately described, and those with <5 leukaemia/myeloid malignancies. 
Studies that employed a case-control design were also excluded, because of the need to fit 
generalised additive models (GAM, see below)17. Apart from the LSS cohort, the datasets 
comprised medically-exposed groups (diagnostic and therapeutic). Analysis was restricted to all 
members of these cohorts with mean cumulative ABM doses <100 mSv; as the Israeli tinea capitis 
cohort did not have any patients exposed to ABM doses <100 mSv, it was excluded from the 
present low-dose analysis but has been included in an ongoing study of these cohorts using 
unrestricted doses.  
Follow-up started generally at the end of diagnosis/treatment for medically-irradiated 
groups, and continued until the earliest of date of cancer diagnosis, date of death, loss to follow-
up or the end of the study; however, for the Massachusetts TB fluoroscopy cohort, follow-up began 
at the date of admission to one of the participating TB treatment institutions. Loss to follow-up is 
a particular concern for the Massachusetts TB fluoroscopy cohort, the scoliosis cohort and the 
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French haemangioma cohort; it was dealt with, as in all other cohorts, by censoring at date of last 
known vital status. Person-years of follow-up in the LSS were adjusted to account for likely in- 
and out-migration from the two cities of the relevant at-risk cohort, using similar survey-derived 
migration rate data as that used in the recent analysis of Hsu et al14. The plausible assumption was 
made in all cohorts that such censoring was non-informative with respect to the endpoints being 
considered. Follow-up in some groups (Canadian TB fluoroscopy cohort, Rochester thymus 
enlargement cohort, Swedish haemangioma cohorts, LSS cohort) began either on the date of 
establishment of the relevant mortality registers (Canadian TB fluoroscopy study - 1 January 1950, 
Rochester thymus enlargement cohort - 1 January 1979), or national cancer registries (Swedish 
haemangioma cohorts - 1 January 1958), or the Japanese national census establishing the LSS 
cohort (1 October 1950). Follow-up in the UK-NCI CT study started at the date of the first CT. 
More detailed information on dates of entry are given in Web-appendix p. 12. 
Further details of the study cohorts are given in Web-appendix pp. 2-3, and of follow-up in 
the individual cohorts in Web-appendix p. 4. The protocol was finalised on 21st March 2016. 
Randomization and masking 
All data received by the statistical analyst (MPL) was in fully anonymised form.  
Procedures 
Radiation dosimetry 
Cumulative doses averaged over the whole-body ABM were calculated for each subject in the 
cohorts according to methods described previously. A variety of different methods were used in 
the component cohorts, but most other than the LSS were based on medical record abstraction of 
the original treatments (including descriptions of treatments received) and relevant patient data. 
For the Massachusetts TB, Canadian TB,  LSS, US spinal curvature, and UK-NCI CT cohorts 
Monte Carlo simulated dosimetry was used, while for all other cohorts a methodology based on 
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physical measurements was used to estimate doses. The LSS dosimetry was particularly complex, 
accounting for both the source terms, radiation transport through air, shielding by terrain and 
physical structures and by the body itself18. Doses were expressed as equivalent doses in Sv. 
Further details are given in Web-appendix pp. 5-7. The pooled analysis generally used the most 
recently calculated set of doses described in these studies, specifically the DS02R1 with 
corrections to Hiroshima and Nagasaki map coordinates and terrain shielding, as employed in the 
latest analysis of the LSS cancer incidence data14. 
Outcomes 
Identification and classification 
The methods/sources of case identification were study-specific. These included: (1) tumour/cancer 
registries (LSS, UK-NCI CT, Göteborg and Stockholm haemangioma); (2) medically validated 
self-reported incidence information (French haemangioma); (3) national and regional cause of 
death registers (Canadian and Massachusetts TB fluoroscopy, US scoliosis, Rochester thymus). 
The groups of malignancies considered in this study were those for which there was previous 
evidence of radiogenicity 1. The number of myelodysplastic syndrome cases/deaths (8) was 
insufficient to evaluate risk. Myelodysplastic syndromes were, however, included in analyses 
combined with acute myeloid leukaemia to reflect recognition of myelodysplastic syndromes 
(previous nomenclature “refractory anaemia”) as a neoplasm and a frequent precursor of acute 
myeloid leukaemia based on the WHO 2001 classification2; myelodysplastic syndromes were also 
included in the group of all myeloid malignancies. As these studies span several decades, during 
which there have been major changes in classification of leukaemia/myeloid neoplasms, and 
included both incidence (5 cohorts) and mortality (4 cohorts) data, we carefully reviewed each of 
the outcomes and developed leukaemia/myeloid disorders groupings (based on International 
Classification of Diseases (ICD) and International Classification of Diseases for Oncology (ICD-
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O) codes) that were relatively homogeneous over calendar time and across studies, and were 
consistent with newer categories based on the World Health Organization (WHO) 2001 
Classification2. The ICD and ICD-O disease endpoints are specified in Web-appendix pp. 8-9. All 
disease coding was centrally reviewed by MPL and MSL in conjunction with individual cohort 
investigators. The principal risk estimate in each instance was the relative risk (RR) of developing 
specific types of leukemia or myeloid neoplasms or groupings of these outcomes based on the 
ionising radiation dose response. However, we also evaluated the excess absolute risk associated 
with radiation exposure. 
We defined the following outcomes of interest, primarily focused on the main radiogenic 
leukaemia malignancies, specifically (a) acute myeloid leukaemia combined with myelodysplastic 
syndromes, (b) acute myeloid leukaemia, (c) chronic myeloid leukaemia, and (d) acute 
lymphoblastic leukaemia.  For comparison with older studies, we evaluated acute leukaemia and 
all leukaemia excluding chronic lymphocytic leukaemia, which also included, as appropriate, 
unspecified leukaemias; chronic lymphocytic leukaemia, now classified as a form of non-Hodgkin 
lymphoma, was excluded as there is little evidence that it is radiogenic 1. Deaths were coded to the 
ICD revisions 6 through 10, and incident outcomes were generally coded to the ICD-O revisions 
2 or 3 (see Web-appendix pp. 8-9, for detailed ICD/ICD-O coding) 2.  
Statistical analysis 
The key covariates evaluated in individual cohorts and in the pooled analysis were selected because 
they are known to modify leukaemia risk or were potentially important effect modifiers1 and were 
available from all of the cohorts. The covariates included sex, age at entry, age first exposed to 
radiation, age last exposed, age attained, year of birth, years since first exposure, years since last 
exposure, and two-year lagged mean ABM dose accumulated in moving windows by time since 
exposure/age at exposure.  
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The primary hypothesis was that radiation would increase risk of all radiogenic leukaemia 
even at low doses. Accordingly, the primary model used for reporting results was the linear relative 
risk (RR) model, a model that has been found to fit radio-epidemiological data well at low doses 
1. We estimated the RR at 100 mSv of mean cumulative ABM dose (RR/100 mSv) for each 
outcome via the fit of the continuous dose-response model, and also assessed the RR for pre-
defined dose-categories using the unexposed group (0 mSv) as the reference category. We 
compared the fit of linear and linear-exponential models in dose to determine whether there was 
possible non-linearity of RR with dose. We also assessed whether the risk varied with time since 
exposure or age at exposure. Mean cumulative ABM doses were lagged by 2 years, chosen a 
priori1, but a sensitivity analysis was conducted assessing lags of 0, 5 and 10 years. The statistical 
power using a 1-sided Poisson trend test with type-I error α=0.05 19 and risk coefficients derived 
from the subset of the publicly available LSS dataset of Hsu et al14 with age at exposure <20 
[ERR/Sv =11.32 for acute myeloid leukaemia, =6.89 for chronic myeloid leukaemia, =21.87 for 
acute lymphoblastic leukaemia], with the given numbers of leukaemias and using the dose 
distribution outlined in Table 1, was 45.3% for acute myeloid leukaemia, 17.5% for chronic 
myeloid leukaemia and 53.3% for acute lymphoblastic leukaemia.  
The models were fitted by Poisson maximum likelihood20 using Epicure 21 and R  22. Tests for 
trend used the likelihood ratio test20. All models were stratified by cohort, sex 
(male/female/unknown), age (0 / 5/ 10 / … / 95 / 100 / >100 years), calendar period of observation 
(1900 / 1910 / 1920 … / 1990 / 2000 / 2010 / 2016), and radiation dose (0 / 0.005 / 0.01 / 0.02 / 0.05 
/ 0.10 Sv). Although not used in the final analysis, the cohort was also stratified by certain other 
variables (years from first exposure, years from last exposure, age at entry, entry year, years from 
study entry); further details are given in Web-appendix p. 10. Likelihood-ratio tests of heterogeneity 
20 across datasets were used, testing statistical compatibility of the RR at 100 mSv (which we shall 
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write henceforth as RR/100 mSv) in each dataset against the common RR/100 mSv in the 
remaining eight cohorts, for each endpoint. GAMs were also fitted 17, in order to assess the 
magnitude of the excess absolute risk (EAR), i.e. the radiation-associated extra cases/deaths per 
person and year of follow-up, for each outcome and cohort. Further statistical details are given in 
Web-appendix p. 28.  
Role of the funding sources 
The funding sources had no role in: study design; data collection, analysis, and interpretation of 
data; writing of the report; or the decision to submit the paper for publication. Only MPL, JSM 
and DC had access to the complete raw data. The corresponding author (MPL) had full access to 
all of the data and the final responsibility to submit for publication. 
Ethical approval 
The study cohort has been declared exempt by the National Cancer Institute Special Studies 
Institution Review Board, because using pre-existing approved data. 
Contributors  
MPL/ABdG/MSL conceived and designed the study, and produced an analytical plan. MPL was 
responsible for acquisition/processing of data and for analysis. DB/CL critically assessed the 
dosimetry. MPL/RW/ABdG/MSL interpreted the results. MPL produced a first draft of the 
manuscript. All authors reviewed the manuscript and provided intellectual input.  
RESULTS 
The combined nine cohorts included 262,573 persons in the studied dose range from 0 to 100 mSv, 
accumulating 5,154,464 person-years of follow-up (Table 1); of 262,573 persons in the cohort, 
132,706 (50.5%) were male and 129,645 (49.4%) were female (Table 1). Among the exposed the 
person-year-weighted mean cumulative ABM dose was 24.0 mSv, the cohort means having a range 
10.2-52.0 mSv (Web-appendix p. 12). The mean age at first exposure was 9.13 years (cohort mean 
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range, 0.11-18.16 years), and the mean years since last exposure was 22.17 years (Web-appendix 
p. 12); 3,509,217 (68.1%) of 5,154,464 person-years of follow-up were accumulated with mean 
lagged ABM dose <10 mSv (Table 1). There were 154 myeloid malignancies, including 79 acute 
myeloid leukaemia, 36 chronic myeloid leukaemia and 8 myelodysplastic syndromes, and also 40 
acute lymphoblastic leukaemia.  The grouped categories used for comparisons included 139 acute 
leukaemia and 221 leukaemias excluding chronic lymphocytic leukaemia.  
There were significant linear dose-response relationships for acute myeloid 
leukaemia+myelodysplastic syndromes, acute myeloid leukaemia, and acute lymphoblastic 
leukaemia (Table 2). The fitted RR/100 mSv were: 3.09 (95% CI 1.41, 5.92, p-trend<0.01) for 
acute myeloid leukaemia+myelodysplastic syndromes; 2.56 (95% CI 1.09, 5.06, p-trend=0.03) for 
acute myeloid leukaemia; and 5.66 (95% CI 1.35, 19.71, p-trend=0.02) for acute lymphoblastic 
leukaemia. There was little evidence of a dose-response for chronic myeloid leukaemia. The dose-
responses are depicted graphically in Figure 1.  For no endpoint was there significant curvilinearity 
(p>0.15) (Web-appendix p. 13), nor was there for the medically-exposed groups of diagnostic and 
therapeutic studies considered separately (p>0.10) (results not shown).  
Table 3 suggests that for acute myeloid leukaemia+myelodysplastic syndromes and acute 
lymphoblastic leukaemia there were statistically significant dose-response relationships for doses 
<50 mSv, with fitted RR/100 mSv 4.88 (95% CI 1.79, 10.17, p-trend<0.01) and 11.52 (95% CI 
1.99, 45.45, p-trend=0.02), respectively, and for acute lymphoblastic leukaemia there was a 
significant dose-response at <20 mSv, with fitted RR/100 mSv 45.09 (95% CI 7.86, 192.50, p-
trend<0.01). For some outcomes, the negative excess relative risk (ERR) derived from the fitted 
model means that the predicted RR/100 mSv (= 1 + ERR x 0.1) becomes negative, and when this 
occurred we set the predicted RR/100 mSv to zero  (see Web-appendix p.28).   
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We examined the effect of time since exposure and age at exposure for the endpoints with 
evidence of a significant dose-response. Although there were indications for all these endpoints of 
a reduction of relative risk with increasing time since exposure, the trends were not statistically 
significant (p>0.2) (Web-appendix pp. 14-15). There was no clear trend in risk with age at 
exposure (Web-appendix pp. 16-17), and there was no indication of modification of risk by 
duration of exposure (Web-appendix p. 18).  
For the grouped disease categories (acute leukaemia, all leukaemia excluding chronic 
lymphocytic leukaemia), there was a significant linear dose-response relationship for acute 
leukaemia with a fitted RR/100 mSv of 2.70 (95% CI 1.40, 4.71, p-trend<0.01) (Table 2) and a 
statistically significant dose-response relationship at <50 mSv but not at <20 mSv (data not 
shown), while for leukaemia excluding chronic lymphocytic leukaemia there was a borderline 
significant increasing trend with dose with a fitted RR/100 mSv of 1.84 (95% CI 0.97, 3.08, p-
trend=0.06) (Table 2).  There was no evidence of curvilinearity for either of these grouped 
endpoints, nor was there for the groups of diagnostic and therapeutic studies considered separately 
(p>0.5) (results not shown).  
Accounting for dose in the period 2-5 years before the point of evaluation of risk significantly 
improved the model fit over that for dose received 5 years for acute myeloid 
leukaemia+myelodysplastic syndromes, acute lymphoblastic leukaemia, acute leukaemia and 
leukaemia excluding chronic lymphocytic leukaemia (all p<0.05), and resulted in marginally 
significant improvements in model fit (0.1>p>0.05) for all myeloid neoplasms and acute myeloid 
leukaemia (Web-appendix p. 19). There were indications (p≈0.05) that accounting for dose in the 
period 0-2 years before point of risk improved the model fit for all myeloid neoplasms, acute 
myeloid leukaemia+myelodysplastic syndromes and acute myeloid leukaemia (Web-appendix p. 
19). In general, the effect of increasing the dose lag period was to decrease the RR and increase 
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the associated p-value, but for acute lymphoblastic leukaemia increasing the lag from 0 year to 2 
years resulted in a notably increased RR (relative to that using the 0 year lag) that became 
significant (Web-appendix p. 20). 
There was little evidence of inter-cohort heterogeneity in risk, with only 3 of the 63 tests 
with adequate convergence exhibiting statistically significant (p<0.05) heterogeneity (Web-
appendix p. 21). More detailed investigation of heterogeneity between the LSS cohort and all the 
combined other cohorts in Web-appendix p. 22 did not suggest any marked discrepancy in risks 
between the LSS and all other cohorts for any endpoint (p>0.25), although risks were somewhat 
higher in the combined medical cohorts than in the LSS for all myeloid endpoints (acute myeloid 
leukaemia+myelodysplastic syndromes, acute myeloid leukaemia, chronic myeloid leukaemia) 
and for the grouped category acute leukaemia, but lower than LSS risks for acute lymphoblastic 
leukaemia and leukaemia excluding chronic lymphocytic leukaemia. There was no further 
suggestion of heterogeneity (p>0.25) if there was further breakdown of the medical cohorts when 
grouping by therapeutic and diagnostic exposure (Web-appendix p. 23), although there were 
indications for most endpoints that risks were slightly higher in the diagnostic group than in the 
therapeutic group, and both tended to be higher than those in the LSS. In addition, although there 
were indications of higher risk for mortality compared with incidence for most malignant 
endpoints (with the exception of acute lymphoblastic leukaemia and leukaemia excluding chronic 
lymphocytic leukaemia), the differences were not statistically significant (p>0.10) (Web-appendix 
p. 24). 
Excess absolute risks were generally small in our study: in the range 0.1-0.4 cases/deaths per 
10,000  person-years at 100 mSv (Web-appendix p. 25);  it should be noted that some of the models 
did not converge for the rarer endpoints. 
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We also analysed the magnitude of the variation of baseline absolute risk by cohort (using 
the LSS as the reference cohort) (Web-appendix p. 26); there was no significant variation between 
the cohort baseline risks for leukaemia excluding chronic lymphocytic leukaemia (p=0.52), 
although there were indications of differences for acute myeloid leukaemia (p=0.02) and acute 
myeloid leukaemia+myelodysplastic syndromes (p=0.03). There were consistent relative 
elevations in the baseline risks for the Göteborg haemangioma and US scoliosis cohorts for all 
three of these endpoints; otherwise, the variations were relatively modest. Although not shown in 
Web-appendix p. 26, because of non-convergence, there were only weak indications of 
heterogeneity of baseline risk by cohort for acute lymphoblastic leukaemia (p=0.31) and chronic 
myeloid leukaemia (p=0.07).  
 
DISCUSSION 
In this pooled analysis of leukaemia and myeloid malignancies in nine cohorts of those exposed in 
childhood or adolescence to ionising radiation with mean cumulative ABM doses <100 mSv we 
observed a significant linear dose-response for acute myeloid leukaemia (with or without 
myelodysplastic syndromes), acute lymphoblastic leukaemia and the grouped category of acute 
leukaemia. A cumulative ABM dose of 100 mSv in childhood/adolescence resulted in the risks of 
acute myeloid leukaemia (with or without myelodysplastic syndromes) and acute leukaemia 
increasing by factors of ~2.6 to 3.1, and the risk of acute lymphoblastic leukaemia increasing by a 
factor of ~5.7 (Table 2). For acute myeloid leukaemia+myelodysplastic syndromes, acute 
lymphoblastic leukaemia and acute leukaemia, risks were significantly elevated also at <50 mSv, 
and for acute lymphoblastic leukaemia at <20 mSv (Table 3). Because these diseases are rare the 
excess absolute risks were small, in the range of 0.1-0.4 excess cases/deaths per 10,000 person-
years at 100 mSv.  There was no significant trend with dose for chronic myeloid leukaemia, which 
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is known to be radiogenic1; the relatively small number of such cases (36) and limited statistical 
power to assess risk at low doses may be a factor in the lack of significant trend of this endpoint 
here, due to the limited follow-up in these cohorts at the ages when chronic myeloid leukaemia 
would be most expected1.  
Although there have been previous pooled analyses of radiation exposure and leukaemia risk 
(e.g., Little et al. 23, Leuraud et al. 24) this study is, to the best of our knowledge,  the first to 
estimate risks of leukaemia and myeloid neoplasms following exposures to low levels of radiation 
during childhood and adolescence.  This is the exposure range that is relevant for most people as 
described above6 but where risks remain uncertain.  In contrast to previous pooled analyses, we 
also incorporated a critical evaluation of the ABM dosimetry. We focused on categories of 
leukaemia and myeloid neoplasms consistent with the WHO 2001 classification2 but also 
evaluated earlier disease categories that allowed us to compare with previous outcome groupings.  
Previous low-dose studies have included those of childhood leukaemias associated with 
natural background exposure, the results of those recently conducted in UK25, Switzerland26, 
Finland27 and France28 being compatible with the RR estimates presented here, as can be seen from 
the degree of overlap of the confidence intervals with central estimates in Web-appendix p. 27. 
There have been a number of other studies of low dose-rates (but not necessarily low cumulative 
doses) of environmental radiation exposure of children and adults. Children exposed to low ABM 
doses as a result of the Chernobyl nuclear accident have been investigated29, and although some 
aspects of these studies (as highlighted by the authors) have been problematic, particularly the 
methods of control selection and the potential for recall bias, the leukaemia risks are compatible 
with those reported here (Web-appendix p. 27). The leukaemia RRs observed in residents near the 
contaminated Techa River in Russia (with 72 cases of leukaemia excluding chronic lymphocytic 
leukaemia among those exposed at all ages), in a small study of persons exposed to 60Co-
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contaminated steel in apartment buildings in Taiwan (with 11 cases of leukaemia excluding 
chronic lymphocytic leukaemia among those exposed at all ages), and in another small study of 
residents of a high-natural background area in India (with 20 cases of leukaemia excluding chronic 
lymphocytic leukaemia among those exposed at all ages) are also consistent with the present 
findings (Web-appendix p. 27), although these studies generally have had limited power because 
the numbers of persons exposed at a young age have been relatively small19 compared to our 
pooled analysis. In addition, there have been many studies examining effects of medical diagnostic 
exposures in the perinatal period in which doses were generally low (<0.1 Gy), but results have 
been difficult to interpret reliably7,30, and in many instances these studies have lacked statistical 
power. However, studies of protracted low-dose, low-dose-rate radiation exposures of workers - 
although not involving childhood/adolescent exposures - have also shown increased leukaemia 
risks, particularly chronic myeloid leukaemia24,31 (Web-appendix p. 27). In summary, in most of 
these other low-dose or low dose-rate studies there are indications of radiation-associated excess 
leukaemia risk, even where these are not conventionally statistically significant, with risk estimates 
that are compatible with our own. 
To the best of our knowledge, all of the substantial cohort studies of leukaemia after low-
dose exposure in childhood/adolescence that meet the eligibility criteria (see Web-appendix pp. 2-
3 for details of the few excluded studies) have been included in this analysis. One limitation of this 
study is that the dosimetry was not uniform between the cohorts, as discussed in Web-appendix 
pp. 2-3, 5. Although the cohorts were exposed at low cumulative doses (<100 mSv) when averaged 
over all ABM compartments, consideration must be given to the heterogeneity in ABM dose (due 
to the specificity of the anatomic sites undergoing diagnostic examination or treatment) for all 
cohorts apart from the LSS. Therefore, a mean cumulative ABM dose of 100 mSv could 
potentially, in some of the therapeutically-exposed cohorts, e.g., the haemangioma cohorts11,12, 
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imply appreciably higher doses, some >1 Gy in certain bone marrow compartments, but a more 
detailed investigation of compartmental bone marrow doses would be needed to fully elucidate 
this. However, this heterogeneity would only matter if there was appreciable non-linearity in the 
leukaemia dose-response in this dose range, but we found no indication of this. The evidence is 
that if risks are being driven by anything in the non-LSS cohorts it is by the diagnostically-exposed 
groups, as is clear from Web-appendix p.23 - in general risks in the therapeutically-irradiated 
cohorts are less than those in diagnostically-exposed groups. Overall, the risk coefficients in the 
medically-exposed cohorts were, in general, slightly higher than, but statistically compatible with, 
those in the LSS (Web-appendix pp. 22-23), suggesting that the effect of any such non-linearity in 
dose response is slight.  
The cohorts had a follow-up period extending over many years, in some groups from the 
early part of the last century. As a consequence, another limitation of this study is that disease 
coding may not be uniform even within a study or across countries. However, there was little 
evidence of this in aggregate – the variation in baseline risks between cohorts was modest, even 
where statistically significant (Web-appendix p. 26). In general, misclassification of a highly 
radiogenic outcome such as leukaemia would be expected to bias risk estimates towards the null, 
if non-differential with respect to exposure. Bias would not be expected if misclassification was 
only due to variations in sensitivity (e.g., for myelodysplastic syndromes, which were not 
diagnosed or reported during the early study periods).  The relative risk models we used were 
stratified by cohort, and so a fortiori by country, and by calendar period, thus accounting for 
differences in baseline rates between countries, or over time, or both; however, more subtle 
variations in diagnosis would not have been captured by our modeling. The mixture of mortality 
and incidence data also complicates the interpretation because, inter alia, there was generally 
increasing treatment success over time, which was not uniform across endpoints; however, as we 
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consider primarily relative risk models, and making the reasonable assumption that within a 
stratum (e.g., defined by cohort, calendar year, age, sex) a fixed proportion of the leukaemia cases 
would go on to die from that cause, independent of dose (i.e., the lethality does not depend on 
dose) one would not expect RR/100 mSv to differ appreciably in mortality compared with 
incidence. The relative risks were somewhat higher in the mortality cohorts than in the incidence 
cohorts, but the risks did not differ significantly in the two groups of cohorts (Web-appendix p. 
24), therefore confirming the reasonableness of the relative risk model and these other 
assumptions. 
It is perhaps notable that there is little evidence in the present study for departure from 
linearity (i.e., with excess risk proportional to dose) in the leukaemia dose-response (Web-
appendix p. 13), suggesting that over the dose range considered a linear dose response is 
appropriate. For this reason, we mostly modelled leukaemia risk using a simple linear relative risk 
model, a model that is commonly used in analysis of radio-epidemiological data 1. The linearity is 
likely to be a reflection of the restriction of attention to the low-dose region (<100 mSv), in which 
dose-response curvature, based on what has been observed elsewhere (e.g., for acute myeloid 
leukaemia in the LSS 14), would not be expected. The restriction of mean cumulative ABM doses 
to <100 mSv, and the consequent reduction in power of the main radiation effect, might reduce 
our ability to detect any modifying effects, so it is not particularly surprising that we found little 
evidence of an influence of time since exposure (Web-appendix pp. 14-15), age at exposure (Web-
appendix pp. 16-17) or duration of exposure (Web-appendix p. 18).  
There was, however, information on latency. The main analyses were conducted with an a 
priori chosen cumulative dose lag of 2 years, implicitly adopting the conventional assumption that 
the dose received within 2 years of leukaemia diagnosis/death does not affect risk1. A sensitivity 
analysis using dose lags of 0, 5 and 10 years showed that a minimum latent period of 2 years was 
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broadly supported and that doses received 2-5 years before diagnosis/death were particularly 
influential, especially for acute lymphoblastic leukaemia (Web-appendix p. 20). There were also 
indications (p≈0.05) of excess acute myeloid leukaemia within 2 years of exposure (Web-appendix 
p. 19). This illustrates the importance of the eight medically-exposed cohorts in this study: 
quantitative information on latency under 5 years cannot be derived from the LSS because the 
follow-up only commenced 5 years after the Japanese atomic bombings (although there was clear 
evidence of an earlier excess of leukaemia among the survivors before the establishment of the 
LSS cohort based on clinical reports32). 
With regard to limitations, the potential effects of selection and survival bias should also be 
considered. Neither the process by which we chose the nine cohorts for study nor the limitation 
within each cohort to those receiving doses <100 mSv should have introduced bias. The subjects 
in some cohorts had to survive until start of follow-up (e.g., Canadian TB, LSS, Swedish 
haemangioma), and in some instances to be eligible for inclusion they had existing medical 
conditions (e.g., TB, haemangioma, scoliosis) or suspected diseases (UK-NCI CT study). There 
has been concern about possible survival or selection bias in the LSS data, although the magnitude 
of any effect of such bias in relation to leukaemia appears to be modest33. There has also been 
concern about reverse causation and confounding by indication in the UK-NCI CT study, although 
for leukaemia with a 2-year dose lag there appears to be little evidence for the former3, and analysis 
excluding those with underlying medical conditions or pre-existing cancer had little effect on CT-
associated leukaemia risk34. Adjustment for socioeconomic status hardly affected either leukaemia 
baseline risk or associated radiation risk in the UK-NCI CT study 3, a finding paralleled in other 
radiation-exposed groups 25. We collected a relatively limited set of variables for each cohort, so 
it is possible that confounding by some unmeasured factor could bias our results. However, the 
cohorts included in our analysis were characterised by few major known risk factors for leukaemia 
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other than radiation1,35, and thus, we posit that confounding is unlikely. The broad consistency of 
the findings across the different cohorts (Web-appendix pp. 21-23) also suggests that any 
shortcomings in the component cohorts, in particular biases and unmeasured confounding factors, 
did not impact materially on the findings of this study.   
Dose error is also possible in all dose estimates that we used (Web-appendix pp. 2-3, 5). 
There are two main types of dose error, classical dose error, which if unadjusted would be expected 
to bias results towards the null 36, and Berkson error which would not be expected to introduce 
bias, although it might increase the variance of estimated trends with dose36. Therefore, in neither 
case would one expect such errors to introduce spurious trends with dose. In some cohorts, in 
particular the LSS, there has been validation of dosimetry via biological markers of exposure 18.  
The strengths of the present study are the prospective designs used in all component cohorts, 
individual ABM dose estimates, relative homogeneity of risk between cohorts (Web-appendix pp. 
21-24, 26), as well as the generally long follow-up periods producing a large number of cases 
exposed at low doses. 
There are radiobiological data supportive of a leukaemia risk following low dose exposure. 
A number of studies have suggested an increase in stable chromosome aberrations and other 
markers of biological damage in peripheral blood lymphocytes (PBL) of nuclear workers and other 
groups with protracted radiation exposures, of a magnitude comparable with that seen in the LSS 
(reviewed in Little et al 37). Such increases in chromosome aberrations have also been observed 
after very low dose irradiation of human PBL exposed ex vivo 38. Furthermore, there is increasing 
evidence that chromosome changes play a major role in carcinogenesis, in particular leukaemia, 
reviewed elsewhere 39, and that the presence of increased frequencies of chromosome aberrations 
in PBL in healthy individuals can be considered as surrogate markers for specific changes 
associated with carcinogenesis, and therefore be indicative of risk 39. Indeed, fusion genes 
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generated by chromosomal translocations have long been known to be consistent with genetic 
abnormalities in paediatric and some adult leukaemias40; in particular the BCR-ABL translocation, 
which  accounts for almost all cases of chronic myeloid leukaemia40. 
In summary, we have documented radiogenic excess risks at mean cumulative ABM doses 
<100 mSv for acute myeloid leukaemia (with or without myelodysplastic syndromes) and acute 
lymphoblastic leukaemia. The relative risks are somewhat higher than, but compatible with, those 
seen in other studies with cumulative doses and dose rates both higher and lower than those studied 
here (Web-appendix p. 27). These findings suggest that there is risk of leukaemia associated with 
low-level exposure to radiation. As most exposures to workers and the general public stem from 
low doses6, the present study, among others, suggests that that the current system of radiological 
protection is prudent and not overly protective. The findings of the present study also add weight 
to efforts already underway (https://www.imagegently.org/) to minimise diagnostic radiological 
imaging, particularly in children, wherever possible. Continuing follow-up of these cohorts using 
up-to-date WHO disease classification combined with a comprehensive and consistent re-
evaluation of dosimetry will be valuable and informative.  
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Table 1. Summary data for persons in nine paediatrically-exposed cohorts with mean cumulative whole-body active bone marrow 
radiation doses ≤100 mSv. 
Class Category 
Person 
years 
Persons 
first at 
risk 
Myeloid 
malignant 
neoplasms 
Acute 
myeloid 
leukaemia + 
myelo-
dysplastic 
syndrome 
Acute 
myeloid 
leukaemia 
Chronic 
myeloid 
leukaemia 
Acute 
lympho-
blastic 
leukaemia 
Acute 
leukaemia 
Leukaemia 
excluding 
chronic 
lymphocytic 
leukaemia 
Leukaemia 
Total  5,154,464 262,573 154 87 79 36 40 139 221 248 
Sex 
male 2,224,910 132,706 82 49 46 17 19 73 118 130 
female 2,927,350 129,645 72 38 33 19 20 65 102 117 
unknown 2,204 222 0 0 0 0 1 1 1 1 
Entry year (calendar 
year of start of follow-
up) 
<1920 56 2 0 0 0 0 0 0 0 0 
1920-1929 37,264 576 2 1 1 1 0 3 4 4 
1930-1939 161,551 4093 10 1 1 3 0 1 13 16 
1940-1949 133,649 4184 3 0 0 2 1 1 14 17 
1950-1959 2,737,850 72,645 90 56 56 22 12 81 121 140 
1960-1969 250,198 5732 3 2 2 1 0 2 6 6 
1970-1979 223,412 7777 3 3 2 0 1 7 9 11 
1980-1989 49,542 2700 1 1 1 0 2 3 3 3 
1990-1999 1,049,670 83,988 31 16 10 6 16 26 34 34 
≥2000 511,275 80,876 11 7 6 1 8 15 17 17 
Calendar year of 
follow-up 
<1920 4 2 0 0 0 0 0 0 0 0 
1920-1929 1,625 576 0 0 0 0 0 0 0 0 
1930-1939 21,927 4,093 1 0 0 0 0 0 1 1 
1940-1949 52,135 4,184 2 0 0 1 0 0 3 3 
1950-1959 546,001 72,645 9 4 4 3 0 8 21 21 
1960-1969 673,594 5,732 11 5 5 3 1 12 22 24 
1970-1979 676,721 7,777 14 10 10 3 3 17 22 23 
1980-1989 682,128 2,700 24 13 13 7 5 19 35 36 
1990-1999 909,478 83,988 32 18 17 12 8 28 47 56 
2000-2009 1,542,880 80,876 58 34 27 7 23 52 66 78 
≥2010 47,977 0 3 3 3 0 0 3 4 6 
Age at entry 
(years) 
0-4 775,339 46,045 10 9 7 0 15 25 29 29 
5-9 997,175 42,872 25 14 14 6 10 25 34 38 
10-14 1,038,600 49,060 32 17 13 11 4 23 37 41 
15-19 997,089 59,309 36 21 20 9 3 25 38 41 
20-29 1,132,410 56,081 39 23 22 7 7 33 53 64 
30-39 147,594 4973 4 2 2 1 1 6 13 16 
40-49 41,721 1969 4 1 1 1 0 2 10 11 
≥50 24,534 2264 4 0 0 1 0 0 7 8 
Years since first 
exposure 
<0 or NA 787,926 34,069 28 8 8 9 3 16 54 60 
0-0.99 12,484 9125 0 0 0 0 0 0 0 0 
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1-1.99 14,311 2159 0 0 0 0 0 0 0 0 
2-4.99 521,372 164,566 8 5 4 2 10 16 20 20 
5-9.99 917,723 44,511 20 11 10 3 11 23 28 28 
10-14.99 595,744 4232 14 8 4 2 5 10 14 14 
15-19.99 373,356 1619 11 8 7 2 0 8 12 12 
20-29.99 555,655 1757 13 8 8 4 4 15 20 20 
≥30 1,375,890 535 60 39 38 14 7 51 73 94 
Attained age 
(years) 
0-4.99 101,297 46,045 1 1 1 0 4 6 6 6 
5-9.99 301,866 42,872 1 1 1 0 9 11 13 13 
10-14.99 444,398 49,060 6 4 3 1 9 13 14 14 
15-19.99 573,247 59,309 17 10 8 3 2 13 17 17 
20-29.99 1,276,510 56,081 27 16 12 7 3 19 30 30 
30-39.99 810,511 4973 15 7 7 5 3 10 19 19 
40-49.99 688,734 1969 19 11 11 5 3 18 27 29 
≥50 957,904 2264 68 37 36 15 7 49 95 120 
Mean cumulative 
active bone marrow 
dose (mSv) 
0-4.99 2,895,460 131,872 89 41 41 25 7 61 124 142 
5-9.99 613,757 50,610 14 7 5 5 5 12 20 21 
10-19.99 651,922 48,056 11 8 6 1 16 23 26 27 
20-49.99 567,610 22,015 24 19 15 3 8 24 29 34 
50-100 425,720 10,020 16 12 12 2 4 19 22 24 
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Table 2. Relative risk at 100 mSv (and 95% CI) derived from fitting a linear relative risk model 
(expression (C1), see Web-appendix p.28) restricted to data in nine paediatrically-exposed 
cohorts with mean cumulative active bone marrow (ABM) radiation doses ≤ 100 mSva 
Endpoint 
Mean ABM dose 
group (mSv) 
Cases / 
deaths Person years 
Relative risk, RR 
(95% CI) 
p-value 
All myeloid 
malignant neoplasms 
(including acute 
myeloid leukaemia, 
chronic myeloid 
leukaemia, other 
myeloproliferative 
cancers and 
myelodysplastic 
syndromes) 
0-4.99 89 2,895,460 1 (=reference)  
5-9.99 14 613,757 0.69 (0.36, 1.25)  
10-19.99 11 651,922 0.64 (0.31, 1.23)  
20-49.99 24 567,610 1.61 (0.98, 2.55)  
50-100 16 425,720 1.28 (0.69, 2.25)  
RR at 100 mSv 154 5,154,464 1.75 (0.81, 3.20) 0.136 
Acute myeloid 
leukaemia + 
myelodysplastic 
syndromes 
0-4.99 41 2,895,460 1 (=reference)  
5-9.99 7 613,757 0.64 (0.25, 1.43)  
10-19.99 8 651,922 0.83 (0.34, 1.80)  
20-49.99 19 567,610 2.33 (1.29, 4.06)  
50-100 12 425,720 1.92 (0.92, 3.74)  
RR at 100 mSv 87 5,154,464 3.09 (1.41, 5.92) 0.008 
Acute myeloid 
leukaemia 
0-4.99 41 2,895,460 1 (=reference)  
5-9.99 5 613,757 0.51 (0.17, 1.27)  
10-19.99 6 651,922 0.64 (0.23, 1.51)  
20-49.99 15 567,610 1.81 (0.95, 3.30)  
50-100 12 425,720 1.81 (0.86, 3.53)  
RR at 100 mSv 79 5,154,464 2.56 (1.09, 5.06) 0.033 
Chronic myeloid 
leukaemia 
0-4.99 25 2,895,460 1 (=reference)  
5-9.99 5 613,757 1.51 (0.44, 4.32)  
10-19.99 1 651,922 0.38 (0.02, 2.04)  
20-49.99 3 567,610 0.82 (0.19, 2.49)  
50-100 2 425,720 0.51 (0.08, 1.98)  
RR at 100 mSv 36 5,154,464 0.36 (0.00b c, 2.36) 0.394 
Acute lymphoblastic 
leukaemia 
0-4.99 7 2,895,460 1 (=reference)  
5-9.99 5 613,757 2.41 (0.64, 8.65)  
10-19.99 16 651,922 4.45 (1.50, 14.08)  
20-49.99 8 567,610 4.20 (1.35, 13.28)  
50-100 4 425,720 3.97 (0.97, 14.15)  
RR at 100 mSv 40 5,154,464 5.66 (1.35, 19.71) 0.023 
Acute leukaemia 
0-4.99 61 2,895,460 1 (=reference)  
5-9.99 12 613,757 0.89 (0.43, 1.71)  
10-19.99 23 651,922 1.29 (0.71, 2.28)  
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20-49.99 24 567,610 1.82 (1.08, 3.00)  
50-100 19 425,720 1.98 (1.10, 3.40)  
RR at 100 mSv 139 5,154,464 2.70 (1.40, 4.71) 0.005 
Leukaemia 
excluding chronic 
lymphocytic 
leukaemia 
0-4.99 124 2,895,460 1 (=reference)  
5-9.99 20 613,757 1.07 (0.62, 1.79)  
10-19.99 26 651,922 1.14 (0.67, 1.89)  
20-49.99 29 567,610 1.54 (0.98, 2.36)  
50-100 22 425,720 1.47 (0.87, 2.36)  
RR at 100 mSv 221 5,154,464 1.84 (0.97, 3.08) 0.059 
aModels stratified by cohort, sex, age and year of follow-up (using intervals of age and year of follow-up defined by 
person-year table, as in Web-appendix p. 10). Unless otherwise stated, all confidence intervals are based on the profile 
likelihood. 
bWald-based CI. 
cpredicted RR = 1+0.1α < 0 so RR set to 0. 
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Table 3. Relative risk (RR) at 100 mSv (and 95% CI) for follow-up restricted to mean 
cumulative active bone marrow (ABM) doses of <100 mSv, <50 mSv and <20 mSva 
 RR at 100 mSv (+95% 
CI) 
Cases/
deaths 
p-value 
Mean cumulative ABM doses < 100 mSv 
Acute myeloid leukaemia + myelodysplastic syndromes 3.09 (1.41, 5.92) 87 0.008 
Acute myeloid leukaemia 2.56 (1.09, 5.06) 79 0.033 
Chronic myeloid leukaemia 0.36 (0.0c, 2.36) 36 0.394 
Acute lymphoblastic leukaemia 5.66 (1.35, 19.71) 40 0.023 
Mean cumulative ABM doses < 50 mSv 
Acute myeloid leukaemia + myelodysplastic syndromes 4.88 (1.79, 10.17) 75 0.007 
Acute myeloid leukaemia 3.41 (0.81, 7.95) 67 0.076 
Chronic myeloid leukaemia 0.63b (0.0c d, 5.81) 34 0.825b 
Acute lymphoblastic leukaemia 11.52 (1.99, 45.45) 36 0.016 
 
Mean cumulative ABM doses < 20 mSv 
Acute myeloid leukaemia + myelodysplastic syndromes 0.53b (0.0, 8.95) 56 0.872b 
Acute myeloid leukaemia 0.0d (0.0c d, 5.90) 52 0.423 
Chronic myeloid leukaemia 0.0d (0.0c d, 9.46) 31 0.357 
Acute lymphoblastic leukaemia 45.09 (7.86, 192.50) 28 0.003 
aModels stratified by cohort, sex, age and year of follow-up (using intervals of age and year of follow-up defined by 
person-year table, as in Web-appendix p. 10). Unless otherwise stated, all confidence intervals are based on the profile 
likelihood. 
bindications of lack of convergence. 
cWald-based confidence limit. 
dpredicted RR = 1+0.1α < 0 so RR set to 0. 
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Figure 1 Relative risk (and 95% CI) by mean cumulative active bone marrow radiation doses for 
(a) acute myeloid leukaemia and myelodysplastic syndromes (MDS), (b) acute myeloid 
leukaemia, (c) chronic myeloid leukaemia, and (d) acute lymphoblastic leukaemia. Solid red line 
gives relative risk = 1, dashed green line the fitted linear relative risk model, with RR at 100 mSv 
taken from Table 2. Dose boundaries used for categories are 0, 5, 10, 20, 100 mSv. 
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RESEARCH IN CONTEXT 
Evidence before this study 
Leukaemia has long been known to be among the most radiosensitive malignancies, and leukaemia 
generally appears sooner than any other cancer after radiation exposure. At moderate-to-high doses 
(>0.5 Sv) there is abundant evidence of radiation-related excess risk for most major leukaemia 
subtypes. Particularly high excess relative risks of leukaemia have been reported following 
radiation exposure in childhood. However, evidence of risk at lower doses is less well established, 
in particular at radiation doses of less than 100 mSv, the level of dose often used to demarcate low 
doses. We conducted PubMed searches at a number of points, and in final form on 29th May 2018 
using the terms “leukaemia” + “radiation” + “medical” + “diagnosis”, “leukaemia” + “radiation” 
+ “medical” + “therapy”. We did not limit the language of publication. We also searched 
comprehensive overviews of the literature prepared by UNSCEAR (2008, 2013) and BEIR VII 
(2006). We chose all available cohort studies reporting on or before 30th June 2014 and with 
adequate dosimetry, with ≥5 leukaemias or myeloid malignancies receiving mean cumulative 
active bone marrow radiation doses >0.005 Sv while aged <21 years, but excluded any studies of 
patients being treated for malignant disease, in which chemotherapy is potentially a strong 
confounder.  
Added value of this study 
Although there have been previous pooled analyses of leukaemia, this study is the first to provide 
quantitative assessments of risk for exposures during childhood and adolescence of less than 100 
mSv. In a pooled analysis of 9 cohorts with 262,573 subjects exposed at a young age to mean 
cumulative active bone marrow doses less than 100 mSv we demonstrated highly significant 
excess risks of acute myeloid leukaemia and acute lymphoblastic leukaemia. Excess risk was also 
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observed for doses under 50 mSv for some endpoints. Exposures 2-5 years before diagnosis/death 
particularly influenced excess risk, with some indications of risk for exposures within 2 years of 
diagnosis. There were few indications of non-linearity in dose response, or inter-cohort 
heterogeneity, in particular between the medically-exposed groups and the Japanese atomic bomb 
survivors.  
Implications of all the available evidence 
The radiation risks in this study are somewhat higher than, but compatible with, those seen in other 
studies, with cumulative doses and dose rates both higher and lower than those studied here. The 
totality of these studies suggests that there is risk of leukaemia associated with low-level exposure 
to radiation. As most exposures to workers and the general public stem from low doses, the present 
study, among others, suggests that that the current system of radiological protection is prudent and 
not overly protective. The findings of the present study also add weight to efforts already underway 
(https://www.imagegently.org/) to minimise diagnostic radiological imaging, particularly in 
children, wherever possible. 
